160 related articles for article (PubMed ID: 19237833)
21. Hypergastrinemia Expands Gastric ECL Cells Through CCK2R
Sheng W; Malagola E; Nienhüser H; Zhang Z; Kim W; Zamechek L; Sepulveda A; Hata M; Hayakawa Y; Zhao CM; Chen D; Wang TC
Cell Mol Gastroenterol Hepatol; 2020; 10(2):434-449.e1. PubMed ID: 32330731
[TBL] [Abstract][Full Text] [Related]
22. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
23. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
Ding XQ; Lindström E; Håkanson R
Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
[TBL] [Abstract][Full Text] [Related]
24. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?
Bonapace ES; Fisher RS; Parkman HP
Dig Dis Sci; 2000 Jan; 45(1):34-9. PubMed ID: 10695611
[TBL] [Abstract][Full Text] [Related]
25. Reversible sustained increase of gastrin and gastric acid secretion in a subgroup of duodenal ulcer patients on long-term treatment with H2 antagonists.
Kohn A; Annibale B; Prantera C; Giglio L; Suriano G; Delle Fave G
J Clin Gastroenterol; 1991 Jun; 13(3):284-90. PubMed ID: 1676714
[TBL] [Abstract][Full Text] [Related]
26. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus.
Nishi T; Makuuchi H; Weinstein WM
Tokai J Exp Clin Med; 2005 Jul; 30(2):117-21. PubMed ID: 16146202
[TBL] [Abstract][Full Text] [Related]
27. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
28. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
29. Histidine decarboxylase expression and histamine metabolism in gastric oxyntic mucosa during hypergastrinemia and carcinoid tumor formation.
Kölby L; Wängberg B; Ahlman H; Modlin IM; Granérus G; Theodorsson E; Nilsson O
Endocrinology; 1996 Oct; 137(10):4435-42. PubMed ID: 8828505
[TBL] [Abstract][Full Text] [Related]
30. Effect of gastric acid-suppressive therapy and biological variation of serum gastrin concentrations in dogs with chronic enteropathies.
Heilmann RM; Berghoff N; Grützner N; Parnell NK; Suchodolski JS; Steiner JM
BMC Vet Res; 2017 Nov; 13(1):321. PubMed ID: 29115998
[TBL] [Abstract][Full Text] [Related]
31. Rebound hypersecretion after inhibition of gastric acid secretion.
Qvigstad G; Waldum H
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):202-8. PubMed ID: 15125689
[TBL] [Abstract][Full Text] [Related]
32. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
33. Use of a five-day test to predict the long-term effects of gastric antisecretory agents on serum gastrin in rats.
Katz LB; Schoof RA; Shriver DA
J Pharmacol Methods; 1987 Dec; 18(4):275-82. PubMed ID: 3695537
[TBL] [Abstract][Full Text] [Related]
34. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.
Robinson M
Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():5-10. PubMed ID: 10555603
[TBL] [Abstract][Full Text] [Related]
35. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
[TBL] [Abstract][Full Text] [Related]
36. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Tsukamoto H; Mizoshita T; Sasaki M; Mizushima T; Tanida S; Ozeki K; Hirata Y; Shimura T; Kataoka H; Kamiya T; Nojiri S; Tsukamoto T; Tatematsu M; Joh T
Asian Pac J Cancer Prev; 2011; 12(4):1049-54. PubMed ID: 21790250
[TBL] [Abstract][Full Text] [Related]
37. Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists.
Dhillo WS; Jayasena CN; Lewis CJ; Martin NM; Tang KC; Meeran K; Todd JF
Ann Clin Biochem; 2006 Mar; 43(Pt 2):153-5. PubMed ID: 16536918
[TBL] [Abstract][Full Text] [Related]
38. Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
Treem W; Hu P; Sloan S
J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):520-6. PubMed ID: 23689261
[TBL] [Abstract][Full Text] [Related]
39. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin.
Helgadóttir H; Metz DC; Yang YX; Rhim AD; Björnsson ES
Dig Liver Dis; 2014 Feb; 46(2):125-30. PubMed ID: 24210828
[TBL] [Abstract][Full Text] [Related]
40. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
